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Abstract. 
 
The spindle assembly checkpoint prevents 
cells whose spindles are defective or chromosomes are 
misaligned from initiating anaphase and leaving mito-
sis. Studies of 
 
Xenopus
 
 egg extracts have implicated the 
Erk2 mitogen-activated protein kinase (MAP kinase) 
in this checkpoint. Other studies have suggested that 
MAP kinases might be important for normal mitotic 
progression. Here we have investigated whether MAP 
kinase function is required for mitotic progression or 
the spindle assembly checkpoint in vivo in 
 
Xenopus
 
 
tadpole cells (XTC). We determined that Erk1 and/or 
Erk2 are present in the mitotic spindle during 
prometaphase and metaphase, consistent with the idea 
that MAP kinase might regulate or monitor the status 
of the spindle. Next, we microinjected purified recom-
binant XCL100, a 
 
Xenopus
 
 MAP kinase phosphatase, 
into XTC cells in various stages of mitosis to interfere 
with MAP kinase activation. We found that mitotic 
progression was unaffected by the phosphatase. How-
ever, XCL100 rendered the cells unable to remain ar-
rested in mitosis after treatment with nocodazole. Cells 
injected with phosphatase at prometaphase or 
metaphase exited mitosis in the presence of nocoda-
zole—the chromosomes decondensed and the nuclear 
envelope re-formed—whereas cells injected with buffer 
or a catalytically inactive XCL100 mutant protein re-
mained arrested in mitosis. Coinjection of constitu-
tively active MAP kinase kinase-1, which opposes 
XCL100’s effects on MAP kinase, antagonized the ef-
fects of XCL100. Since the only known targets of MAP 
kinase kinase-1 are Erk1 and Erk2, these findings argue 
that MAP kinase function is required for the spindle as-
sembly checkpoint in XTC cells.
 
I
 
nhibitors
 
 of microtubule polymerization arrest most
cells in a prometaphase-like stage, indicating that a
checkpoint monitors chromosome alignment and/or
the status of the spindle and regulates the metaphase to
anaphase transition. This safeguard helps to ensure accu-
rate transmission of genetic information to the daughter
cells. Defects in cell cycle checkpoints increase the fre-
quency of chromosome loss and gene amplification and
may play a role in tumor progression (Hartwell et al., 1994;
Hartwell and Weinert, 1989; Murray, 1994, 1995).
In the budding yeast 
 
Saccharomyces cerevisiae
 
, spindle
disruption arrest depends on the products of three 
 
MAD
 
(mitotic arrest defective) genes (Hardwick and Murray, 1995;
Hardwick et al., 1996; Li et al., 1994), three 
 
BUB
 
 (budding
uninhibited by benzimidazole) genes (Hoyt et al., 1991;
Roberts et al., 1994), and MPS1 (multipolar spindle; Lauze
et al., 1995; Weiss and Winey, 1996). Vertebrate homologs of
one of these genes, 
 
MAD2
 
, have recently been identified
and found to be important for the spindle assembly check-
point,  indicating that the mechanisms underlying this
checkpoint are likely to be well conserved evolutionarily
(Chen et al., 1996; Li and Benezra, 1996).
In a wide variety of organisms, phosphoprotein dephos-
phorylation is essential for progression from metaphase to
anaphase. Certain fission yeast and 
 
Drosophila
 
 mutants
with altered phosphatase activity exhibit metaphase ar-
rest phenotypes (Kinoshita et al., 1991; Mayer-Jaekel et al.,
1993; Ohkura et al., 1989). Studies with phosphoepitope-
specific antibodies have also implicated dephosphorylation
in progression to anaphase (Campbell and Gorbsky, 1995;
Gorbsky and Ricketts, 1993; Nicklas et al., 1995). Inactiva-
tion of phosphatases that are necessary for anaphase, or
activation of kinases that oppose progression into anaphase,
could be the mechanism through which defective spindles
and misaligned chromosomes bring about mitotic arrest.
Minshull et al. (1994) implicated the Erk2 or p42 mito-
gen-activated protein kinase (MAP kinase)
 
1
 
 protein in the
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spindle assembly checkpoint through studies of cytoplas-
mic extracts of 
 
Xenopus
 
 eggs, a system that offers great
biochemical manipulability. Previous work had shown that
even though 
 
Xenopus
 
 eggs and early embryos lack the
DNA synthesis checkpoint—DNA synthesis inhibitors do
not affect blastomere cleavage—this checkpoint can be re-
constituted by the addition of sperm nuclei to a concentra-
tion of 
 
z
 
250 per 
 
m
 
l (higher than the concentration of nu-
clei in an early embryo, but lower than the concentration
of 
 
z
 
250,000 nuclei per 
 
m
 
l for a 4 pl somatic cell; Dasso and
Newport, 1990). Minshull et al. (1994) examined whether
the spindle assembly checkpoint could also be reconsti-
tuted by addition of sperm nuclei to the extracts. They found
that it could: extracts supplemented with 
 
z
 
9,000 nuclei
per 
 
m
 
l arrested in a mitotic state in the presence of no-
codazole, and destruction of cyclins B1 and B2 (but not
cyclin A1) was suppressed. They also noted that p42 MAP
kinase underwent sustained activation in the nocodazole-
treated, arrested extracts. Addition of a MAP kinase phos-
phatase (mouse Mkp-1) that can dephosphorylate and in-
activate p42 (Erk2), p44 (Erk1), and p38 (Hog1) MAP
kinases, but is minimally active towards other phospho-
proteins (Alessi et al., 1993; Groom et al., 1996; Keyse and
Emslie, 1992; Sun et al., 1993), resulted in inactivation of
the p42 MAP kinase, destruction of cyclins B1 and B2, and
release of the extracts from mitotic arrest. These studies
showed that MAP kinase, or some closely related protein,
is essential for the spindle assembly checkpoint in this re-
constituted in vitro system.
Although MAP kinases are probably best known for their
transient activation when quiescent cells are prompted to
reenter the cell cycle, they are also activated during mei-
otic maturation in oocytes (Ferrell et al., 1991; Haccard et al.,
1990; Jessus et al., 1991; Posada et al., 1991). MAP kinase
activation triggers or facilitates the activation of Cdc2 (Go-
toh et al., 1995; Haccard et al., 1995; Huang and Ferrell,
1996
 
a
 
; Kosako et al., 1994), although the mechanism through
which MAP kinase regulates Cdc2 activity remains to be
elucidated. Given the similarities between meiotic and mi-
totic M-phase regulation, these findings raise the possibil-
ity that MAP kinase might participate in the activation of
Cdc2 at the G2-M transition in somatic cells.
MAP kinase may contribute to M phase in other ways as
well. Gotoh et al. (1991
 
b
 
) observed that MAP kinase is ca-
pable of increasing the dynamic instability of microtubules
in 
 
Xenopus
 
 egg extracts, which raises the possibility that
MAP kinase activity may be necessary for microtubule re-
organization at the onset of M phase.
In this study we set out to evaluate the hypotheses that
p42 or p44 MAP kinase function is important for entry into
mitosis in somatic cells, as suggested by studies of meiotic
maturation; for establishing a mitotic spindle, as suggested
by studies of microtubule dynamics in cytoplasmic 
 
Xeno-
pus
 
 egg extracts; or for spindle assembly checkpoint con-
trol, as suggested by studies of nocodazole-treated, sperm
nucleus–supplemented 
 
Xenopus
 
 egg extracts. We chose to
carry out our studies in the 
 
Xenopus
 
 tadpole cell line
(XTC), both because of the availability of good quality ho-
mologous reagents for perturbing MAP kinase function,
and because XTC cells remain relatively flat during mito-
sis, facilitating microscopic examination of mitotic cells.
Here we demonstrate that MAP kinase is present in the
spindle during specific stages of M phase, consistent with
the possibility that MAP kinase regulates the spindle or
monitors the status of the spindle. Microinjection of a spe-
cific MAP kinase–inactivating enzyme, 
 
Xenopus
 
 MAP ki-
nase phosphatase-1 or XCL100, has no obvious effect on
normal mitotic progression but renders cells unable to
maintain a mitotically arrested state when mitosis is dis-
rupted by nocodazole treatment. Our results provide in
vivo support for the hypothesis that p42 and/or p44 MAP
kinase function are required for the spindle assembly
checkpoint.
 
Materials and Methods
 
Cell Culture
 
The 
 
Xenopus
 
 tadpole cell line (XTC) was obtained from Dr. Tim Stearns
(Stanford University) and grown at room temperature in 70% L-15 me-
dium supplemented with 10% FBS. Cells to be used for microinjection
were plated onto coverslips with photoetched locator grids (Bellco Glass,
Inc., Vineland, NJ) and grown for at least 2 d.
 
Antibodies
 
The rabbit MAP kinase antiserum X15 was raised against a 
 
Xenopus
 
 p42
MAP kinase COOH-terminal peptide (Hsiao et al., 1994) and affinity pu-
rified on a peptide column. Affinity-purified X15 was tested for its speci-
ficity by immunoblotting XTC cell lysates. An Erk1 antibody (C-16) was
obtained from Santa Cruz Biochemicals (Santa Cruz, CA). MKK-1 antise-
rum 662, raised against a 
 
Xenopus
 
 MKK-1/Mek-1 NH
 
2
 
-terminal peptide,
has been described previously (Hsiao et al., 1994). An antibody that rec-
ognizes active, but not inactive, Erks 1 and 2 was purchased from Promega
(Madison, WI). XCL100 antiserum was raised and provided by M.L. So-
haskey (Stanford University).
 
Preparation of Cell Lysates
 
XTC cells were grown to near confluence. Cells were trypsinized and col-
lected by centrifugation. SDS sample buffer was added to the pelleted
cells.
Lysates from 
 
Xenopus
 
 oocytes or electrically activated eggs, containing
nonphosphorylated p42 MAP kinase, and from progesterone-treated oo-
cytes or nonactivated eggs, containing phosphorylated p42 MAP kinase,
were prepared as described (Ferrell et al., 1991; Murray, 1991).
 
Immunoblotting
 
Oocyte, egg, and XTC cell lysates were separated by SDS 10% polyacryl-
amide gel electrophoresis, transferred to an Immobilon-P membrane (Mil-
lipore Corp., Bedford, MA), and probed with the affinity-purified X15
antibody at 1 
 
m
 
g/ml followed by affinity-purified alkaline phosphatase–con-
jugated goat anti–rabbit IgG at 1:3,000 (Sigma Chemical Co., St. Louis, MO). 
 
Construction of an XCL100 Expression Plasmid
 
The wild-type XCL100 cDNA was inserted into pGEX-4T for expression
in bacteria as follows: gel-purified 1.6-kb BamHI–XhoI fragment, which
contained all but the NH
 
2
 
-terminal 130 bp of the XCL100 coding region
plus 0.66 kb of the 3
 
9
 
-untranslated region, was ligated into pGEX-4T to
yield pGEX-
 
D
 
N. The NH
 
2
 
-terminal 130-bp fragment was obtained by PCR,
with the 5
 
9
 
 primer consisting of a synthetic BamHI site fused to the codon
for the initiator methionine and the 3
 
9
 
 primer spanning the natural
XCL100 BamHI site. The fidelity of the PCR product was verified by se-
quencing. The PCR product was digested with BamHI, gel purified, and
ligated into the BamHI site of pGEX-
 
D
 
N to yield pGEX-XCL100.
A cDNA for the catalytically inactive phosphatase XCL100 C260S, which
has a serine residue in place of the essential active site cysteine residue,
was generated by PCR by M.L. Sohaskey. An EcoRI–NheI fragment span-
ning the mutagenized codon was excised and ligated into pGEX-XCL100
to yield pGEX-XCL100 C260S. The protein products of the wild-type and
mutant forms of pGEX-XCL100 are fused to the COOH terminus of glu-
tathione-
 
S
 
-transferase (GST). 
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Expression and Purification of XCL100
 
Overnight cultures of 
 
Escherichia coli
 
 transformed with pGEX-XCL100
or pGEX-XCL100 C260S were grown and lysed essentially as described
(Wang et al., 1996). The clarified cell extracts were recycled over a 2.5-ml
column of glutathione agarose (Sigma Chemical Co.) for 5 h at 4
 
8
 
C. The
column was washed with 10 vol of PBS, and fusion proteins were eluted
with 50 mM Tris, pH 8.0, containing 15 mM glutathione. Fractions were
assessed for MAP kinase phosphatase activity, as described below, and
peak fractions were pooled. As has been previously reported, XCL100
and XCL100 C260S manifested substantial proteolytic degradation; much
of the glutathione agarose–purified protein was digested back to the GST
moiety (see Fig. 4 
 
A
 
; see also Sun et al., 1993). However, we were able to
obtain purified full-length XCL100 or XCL100 C260S proteins by anion
exchange chromatography. Peak fractions from the glutathione agarose
column were applied to a Mono-Q column (Pharmacia Fine Chemicals,
Piscataway, NJ) equilibrated with 20 mM Tris, pH 7.8, 20 mM NaCl, and
2 mM DTT. Proteins were eluted from the column with a linear gradient
of 20 mM–1 M NaCl. Activity was recovered in the fractions containing
640–660 mM NaCl, pooled, and dialyzed against the microinjection buffer
(130 mM KCl, 10 mM NaPipes, pH 7.0, and 1 mM MgCl
 
2
 
 ). Material ob-
tained after the glutathione agarose purification step and after the Mono-Q
step exhibited indistinguishable biochemical and biological activities.
We found that the biochemical activity of XCL100 did not survive mul-
tiple freeze-thaw cycles or prolonged storage at 4
 
8
 
C. Therefore, for studies
described below, we used XCL100 and XCL100 C260S that had been
stored at 4
 
8
 
C for no more than 48 h, or, in some experiments, used
XCL100 that had been frozen in 10% glycerol, stored at 
 
2
 
70
 
8
 
C, and
thawed just before its use.
 
Other Recombinant Proteins
 
A pRSET-based plasmid for a constitutively active, His
 
6
 
-tagged mutant of
human MKK-1/Mek-1 (with Ser 218 replaced by Glu, Ser 222 replaced by
Asp, and a deletion of amino acids 32–51, hereafter denoted MKK-1*)
was provided by Natalie Ahn (University of Colorado, Boulder). An
NheI–HindIII fragment containing the MKK-1* coding region was sub-
cloned into pFastBac1 for generation of baculoviruses. MKK-1* was ex-
pressed in insect cells and purified to homogeneity by nickel-chelate chro-
matography by Ramesh Bhatt (Stanford University).
Hexahistidine-tagged, kinase-minus (K52R) rat Erk2 was expressed in
 
E. coli
 
 and purified by Chi-Ying Huang (Stanford University; Huang and
Ferrell, 1996
 
a
 
) from a plasmid provided by Melanie Cobb and Tom Gep-
pert (University of Texas Southwestern Medical Center) (Robbins et al.,
1993). A pT7-7–based plasmid for expression of hexahistidine-tagged 
 
Xe-
nopus
 
 Erk2 was engineered from a 
 
Xenopus
 
 Erk2 cDNA provided by
Jonathan Cooper and Jim Posada (Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA), and it was expressed in 
 
E. coli
 
 and purified by Ramesh
Bhatt.
 
In Vitro Phosphatase Activity Assay
 
To prepare phosphorylated Erk2 for use as a substrate in an XCL100
phosphatase assay, we incubated recombinant kinase-minus rat Erk2 with
active MKK-1 that had been obtained from 
 
Xenopus
 
 egg lysates by immu-
noprecipitation with antibody 662 (Hsiao et al., 1994), and MgATP. The
XCL100 phosphatase assay was performed by incubating phosphorylated
MAP kinase with purified XCL100 fusion proteins in phosphatase reac-
tion buffer (50 mM Hepes, pH 7.5, 1 mg/ml BSA, 2 mM DTT, and 2 mM
EDTA) in a final reaction vol of 60 
 
m
 
l. After incubation for 30 min at
30
 
8
 
C, the reaction was stopped by adding SDS sample buffer, and the sam-
ple was boiled. Proteins were separated by SDS 10% polyacrylamide gel
electrophoresis and immunoblotted as described above. Dephosphoryla-
tion of Erk2 was detected as a shift of the blotted Erk2 band to a lower ap-
parent molecular weight.
 
MAP Kinase Assay
 
MAP kinase activity was assessed by a myelin basic protein phosphoryla-
tion assay essentially as described (Huang and Ferrell, 1996
 
a
 
). Reaction
mixtures were analyzed by SDS 12.5% polyacrylamide gel electrophore-
sis, proteins were transferred to an Immobilon P membrane, and incorpo-
ration of 
 
32
 
P into myelin basic protein was quantified using a phosphorim-
ager (Molecular Dynamics, Sunnyvale, CA).
 
Microinjection and Nocodazole Treatment
 
Micropipettes were pulled on a horizontal pipette puller (Sutter Instru-
ment Co., Novato, CA). Proteins were microinjected with a Narishiga
manual microinjector (Greenvale, NY). The needle concentration of
XCL100 protein (both wild-type and mutant forms) was 1.5 
 
m
 
M, and MKK-
1* was 10 
 
m
 
M when MKK-1* was injected alone, and 5 
 
m
 
M when MKK-1*
was coinjected with XCL100.
For checkpoint control experiments, we first microinjected the appro-
priate protein(s), and then aspirated the medium and added fresh F-15
medium containing nocodazole at 50 ng/ml. Cells were viewed with a 
 
3
 
40
phase-contrast objective (NA 0.75) on an inverted microscope (Carl Zeiss,
Inc., Thornwood, NY) equipped with a CCD camera and recorded with
an optical disk recorder (Panasonic, Secaucus, NJ) for up to 4 h after in-
jection or treatment with the drug.
 
Immunofluorescence
 
XTC cells were grown on coverslips, fixed with methanol (
 
2
 
20
 
8
 
C) for 6
min, and then treated with a microtubule stabilizing buffer (25 mM imida-
zole, pH 7.0, 10 mM KCl, 1 mM MgSO
 
4
 
, 10 mM EGTA, and 20% glyc-
erol) containing 0.1% Triton X-100 (Pierce Chemical Co., Rockford, IL),
followed by washing with PBS. XTC cells were blocked in 3% milk, and
then stained with affinity-purified X15 at 8 
 
m
 
g/ml followed by affinity-
purified FITC-conjugated goat anti–rabbit IgG at 1:100 (Kirkegaard &
Perry Laboratories Inc., Gaithersburg, MD). For triple labeling, the cells
were incubated sequentially with X15 and then mouse monoclonal anti–
 
b
 
-tubulin antibody (Amersham Corp., Arlington Heights, IL) at 1:100.
FITC-conjugated anti–rabbit IgG (1:100) and affinity-purified Texas red–
conjugated goat anti–mouse IgG (1:200; Jackson ImmunoResearch Labo-
ratories, Inc., West Grove, PA) were mixed and applied. Finally, chromo-
somes were stained with 4
 
9
 
,6-diamidino-2-phenylindole (DAPI) at 1 
 
m
 
g/
ml for 30 s. Each step was followed by four 10-min rinses with PBS.
Images were obtained using either a 
 
3
 
100, 1.3 NA objective on a Zeiss
microscope equipped with a cooled CCD camera or a 
 
3
 
40, 0.9 NA objec-
tive on a Zeiss microscope equipped with a conventional 35-mm camera.
Figure 1. The specificity of antibody
X15. Immunoblots of lysates from
XTC cells (lane 1), G2-phase oocytes
(lane 2), and M-phase oocytes (lane 3)
were probed with X15. XTC cells ex-
hibited two bands: a lower band that
comigrated with nonphosphorylated
Erk2, and an upper band that comi-
grated with both Erk1 and phosphory-
lated Erk2. The upper band was identi-
fied as Erk1, rather than phosphorylated
Erk2, based on its cross-reactivities
with other Erk1 and Erk2 antisera, and
on the fact that it did not shift to a
lower apparent molecular weight when
lysates were treated with XCL100 (not
shown). 
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Results
 
Erk2/p42 MAP Kinase Localizes at the Mitotic
Spindle after Nuclear Envelope Breakdown and
Leaves the Spindle before Anaphase
 
The localization of some cell cycle regulators provides a
clue to their function. Accordingly, we examined the local-
ization of MAP kinase during M phase in a tissue-culture
cell line, XTC. We determined the most suitable of several
antisera for immunolocalization studies to be X15, an anti-
peptide antiserum raised against a 
 
Xenopus
 
 Erk2 (p42)
MAP kinase COOH-terminal peptide (Hsiao et al., 1994).
X15 recognizes active and inactive forms of 
 
Xenopus
 
 Erk2
equally well, both in immunoprecipitations (nondenatur-
ing conditions) and in immunoblots (denaturing condi-
tions; Hsiao et al., 1994; Fig. 1).
Figure 2. Immunolocalization
of MAP kinase at different
mitotic stages. XTC cells
were fixed, permeabilized,
and subjected to triple label
staining with DAPI, X15, and
a b-tubulin antibody (A–F), or
with DAPI, X15 preimmune
serum, and the tubulin anti-
body (G). 
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We affinity purified X15 antibody on a peptide column
and characterized the affinity-purified X15 for its specific-
ity in total XTC lysates. Affinity-purified X15 recognized
two bands on immunoblots (Fig. 1), corresponding to 
 
Xe-
nopus
 
 Erk1 and Erk2.
We then carried out immunofluorescence studies of
XTC cells using affinity purified X15. Fig. 2 shows the re-
sults of triple label staining with X15 (fluorescein staining),
antitubulin antiserum (Texas red), and DAPI for DNA
staining. In interphase, MAP kinase was diffusely distrib-
uted through the cytoplasm (Fig. 2 
 
A
 
). There was no obvi-
ous concentration of MAP kinase in the interphase micro-
tubules.
When cells entered prometaphase, much of the MAP ki-
nase staining remained diffusely cytoplasmic, but some of
the staining became concentrated on the spindle (Fig. 2 
 
B
 
).
MAP kinase was detectable on the spindle during early
prometaphase just after nuclear envelope breakdown, and
the staining increased during metaphase (Fig. 2, 
 
B–C
 
). Dur-
ing anaphase, the intensity of the MAP kinase staining of
the spindle decreased to about the level of intensity of
general cytoplasmic staining (Fig. 2 
 
D
 
). Thus, the spindle-
like “fingers” of MAP kinase staining seen in Fig. 2 
 
D
 
 could
include some spindle-associated MAP kinase, but could
also simply represent fingers of cytoplasm between MAP
kinase–free masses of chromosomes. By late anaphase, the
intensity of MAP kinase staining around the spindle was
lower than that in other regions of the cell (Fig. 2 
 
E
 
). MAP
kinase was not detectable in the midbody, the prominent
microtubule-containing structure that forms between the
two daughter cells during cytokinesis (Fig. 2 
 
F
 
). Thus, MAP
kinase was found to be associated with the spindle during
prometaphase and metaphase and to dissociate from the
spindle and midbody, or to become inaccessible to anti-
body staining during anaphase and cytokinesis.
Preimmune serum yielded no spindle staining (Fig. 2 
 
G
 
),
indicating that the spindle staining observed with affinity-
purified X15 was specific. Preincubation of X15 with the
peptide against which it was raised markedly decreased
the intensity of both spindle and cytoplasmic staining (Fig.
3). Finally, single label immunofluorescence studies with
affinity-purified X15 showed spindle staining, confirming
that the results seen in the triple label studies were not due
to cross-reactivity between secondary antibodies or leak-
age between the fluorescein and Texas red filters (Fig. 3).
These findings demonstrate that Erk1 or Erk2 is present
in the spindle during specific subphases of mitosis. This
places MAP kinase in an appropriate position to be in-
volved in either regulating the spindle or relaying informa-
tion about the status of the spindle.
 
Purified Bacterially Expressed GST-XCL100 
Dephosphorylates Erk2 MAP Kinase In Vitro
 
We set out to determine whether, in intact XTC cells, MAP
kinase activation might be necessary to trigger or maintain
Cdc2 activation, as appears to be the case during meiotic
maturation (Gotoh et al., 1995; Haccard et al., 1995; Huang
and Ferrell, 1996
 
a
 
; Kosako et al., 1994
 
b
 
); MAP kinase might
be needed to maintain the dynamic properties of the
M-phase microtubules, as suggested by studies of inter-
phase 
 
Xenopus
 
 egg extracts (Gotoh et al., 1991
 
b
 
); or MAP
kinase activity might be required for the spindle assembly
checkpoint, as suggested by studies of nocodazole-treated,
nucleus-supplemented cycling 
 
Xenopus
 
 egg extracts (Min-
shull et al., 1994). The approach chosen was to microinject
a 
 
Xenopus
 
 MAP kinase phosphatase, XCL100, which
could prevent or reverse MAP kinase activation, and de-
termine the consequences by time-lapse video microscopy.
XCL100 and its homologs CL100 (human) and Mkp-1
(mouse) are dual-specificity phosphatases that dephosphor-
ylate the phosphothreonine and phosphotyrosine regula-
tory sites of MAP kinase, thereby inactivating MAP kinase
(Alessi et al., 1993; Lewis et al., 1995; Sun et al., 1993).
CL100/Mkp-1 proteins are highly specific for the p42 Erk2,
p44 Erk1, and p38 Hog1 MAP kinases in vitro (Alessi et
al., 1993; Groom et al., 1996; Keyse and Emslie, 1992; Sun
et al., 1993). Transient expression of Mkp-1 in COS cells
Figure 3. Single label immu-
nolocalization of MAP kinase.
XTC cells were fixed, permeabi-
lized, stained with DAPI (not
shown) and X15 or X15 plus
blocking peptide (35 mM), and
examined by fluorescence and
phase microscopy. The cell
shown is in metaphase. 
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leads to selective dephosphorylation of MAP kinase from
the spectrum of phosphotyrosine-containing proteins (Sun
et al., 1993), indicating that XCL100/Mkp-1 proteins are
highly specific in vivo as well.
We expressed wild-type XCL100 and an engineered cat-
alytically inactive version of XCL100, with Cys 260 mu-
tagenized to Ser (XCL100 C260S), as GST fusion proteins
in bacteria. The proteins were purified to homogeneity by
glutathione affinity chromatography and Mono-Q anion
exchange chromatography (Fig. 4 
 
A). The purified wild-
type XCL100 protein potently dephosphorylated p42 MAP
kinase (Fig. 4 B) but not Mos, Mek, or Rsk (Huang, C.Y.-F.,
unpublished data), other enzymes in the MAP kinase path-
way. The mutant XCL100 C260S protein did not dephos-
phorylate MAP kinase (Fig. 4 B).
We then carried out in vitro studies to determine whether
it was likely that we could achieve a high enough concen-
tration of XCL100 by microinjection to interfere with Erk1
and Erk2 activation. By microinjection, we should be able
to increase the cell’s XCL100 concentration by z75 nM
(assuming we can inject 50 fl into a 1 pl cell, and given that
the needle concentration of XCL100 was 1.5 mM). The
abundance of MKK-1 and Erk1/2 in several cell lines has
been estimated to be on the order of 1 mM (Ferrell,
1996b). In Xenopus oocyte extracts, activation of z25% of
the MKK-1 results in activation of z50% of the Erk2
(Huang and Ferrell, 1996b). We added various dilutions of
XCL100 to a mixture of recombinant Xenopus Erk2 (1 mM)
and MKK-1* (250 nM), in the presence of MgATP, and let
the system reach steady state. We found that 38 nM
XCL100  was sufficient to half-maximally inhibit Erk2 ac-
tivation, 75 nM XCL100 inhibited Erk2 activation by
87%, and 150 nM XCL100 inhibited Erk2 activation com-
pletely (Fig. 4 C). Based on these in vitro titrations, it ap-
pears reasonable to expect XCL100 microinjection to have
an effect on MAP kinase activation in vivo, provided the
microinjected phosphatase is not rapidly degraded or inac-
tivated.
Microinjection of MAP Kinase Phosphatase Does Not 
Affect Mitotic Progression
To test whether interfering with MAP kinase activation by
XCL100 microinjection would affect the mitotic progression,
we microinjected XTC cells at different stages of mitosis—
prophase, prometaphase, metaphase, and anaphase—with
purified XCL100 protein, and then followed the injected
cells by time-lapse video microscopy. We found that 20 out
of 20 cells injected with XCL100 (needle concentration 1.5
mM, estimated intracellular concentration 75 nM) pro-
gressed to metaphase, initiated anaphase, and cleaved, all
with normal kinetics (Table I). These findings indicate that
either a high level of MAP kinase activity is not required
for normal mitotic progression, or the intracellular con-
Figure 4. Purification and characterization of the GST–XCL100 fusion protein. (A) Purification of bacterially expressed GST-XCL100.
Full-length GST-XCL100 migrates at z67 kD. The prominent band at z27 kD in the glutathione agarose purified sample is GST. After
Mono-Q purification, full-length GST-XCL100 was the main band detectable by Coomassie staining, and a single band was detectable
by XCL100 immunoblotting. (B) Activity of GST-XCL100. This panel shows a MAP kinase immunoblot of recombinant nonphosphor-
ylated rat Erk2 (MK), and phosphorylated rat Erk2 (MK-P) incubated with no phosphatase, with GST-XCL100, or with the inactive
GST-XCL100 C260S mutant. (C) In vitro titration of GST-XCL100 activity. Various concentrations of GST-XCL100 were mixed with
250 nM MKK-1* and 1 mM Xenopus Erk2, and the system was allowed to reach steady state. MAP kinase activity was determined by a my-
elin basic protein phosphorylation assay.Wang et al. MAP Kinase and the Spindle Assembly Checkpoint 439
centration of XCL100 achieved by microinjection was not
sufficient to substantially interfere with MAP kinase acti-
vation. The fact that some of the same preparations of
XCL100 were found to interfere with checkpoint control,
as described below, argues for the first possibility.
Microinjection of MAP Kinase Phosphatase Causes 
Mitotically Arrested Cells to Exit Mitosis without Sister 
Chromatid Segregation, Karyokinesis, or Cytokinesis
Next, we tested the hypothesis that MAP kinase function
is required for the spindle assembly checkpoint, as sug-
gested by experiments in nucleus-supplemented Xenopus egg
extracts (Minshull et al., 1994). Treatment of noninjected,
mitotic XTC cells with nocodazole (0.05 mg/ml) resulted in
rapid disappearance of the spindle (generally within 3 min),
including the kinetochore microtubules (data not shown).
Cells then remained blocked in a pseudo-prometaphase
stage with scattered chromosomes for up to 12 h.
Our initial approach to determining whether XCL100
microinjection might interfere with this arrest was to ar-
rest XTC cells in a pseudo-prometaphase stage by treat-
ment with nocodazole, then inject XCL100 protein, and
finally follow the cells to see whether they would exit mi-
tosis. However, the nocodazole-treated XTC cells proved
too fragile to microinject; they often swelled and died (as
indicated by cessation of cytoplasmic streaming) immedi-
ately after injection.
Therefore, we chose to identify and microinject mitotic
cells first, and then immediately thereafter treat them with
nocodazole. We found that cells injected with wild-type
XCL100 protein during prometaphase or metaphase grad-
ually began to exit mitosis z45 min to 1 h after nocodazole
treatment, without re-forming spindles or carrying out sis-
ter chromatid segregation, karyokinesis, or cytokinesis (Ta-
ble I). Initially, the chromosomes became clustered and
then decondensed, and finally the nuclear envelope re-
formed and nucleoli appeared (Fig. 5). The resulting cells
resembled typical, flat interphase cells, except that the
cells and their nuclei were unusually large (Fig. 5). When
cells were injected during prophase (before nuclear enve-
lope breakdown) and then treated with nocodazole, they
did not exit mitosis.
We carried out a variety of experiments to assess the
specificity of the effects of XCL100 microinjection on meta-
phase arrest. First, the possibility that cells escaped the
checkpoint control because of microinjection trauma was
assessed by injection of buffer alone. All cells (10/10) in-
jected with buffer behaved the same as noninjected ones:
they remained mitotically arrested for at least 4 h after no-
codazole treatment, indicating no detectable effect of mi-
croinjection per se (Table I).
Next, we determined whether the effect of XCL100 on
mitotic arrest was dependent on its phosphatase activity.
We injected cells with purified recombinant XCL100 C260S
protein, the inactive mutant form, at a needle concentra-
tion of 1.5 mM. All cells (17/17) injected with XCL100 C260S
protein maintained normal mitotic arrest for at least 4 h
when treated with nocodazole (Fig. 5; Table I). This result
indicates that the effect of XCL100 on the spindle assem-
bly checkpoint is dependent on its phosphatase activity.
We also set out to determine whether any active Erk1 or
Erk2 was present in nocodazole-arrested XTC cells, as
should be the case if the effects of XCL100 were due to in-
activation of one of these MAP kinases. We prepared ly-
sates from asynchronous XTC cells, from cells incubated
for various lengths of time (15 min through 7 h) with no-
codazole, and from cells shaken off of a plate of cells that
had been treated with nocodazole for 16 h. We subjected
these samples to immunoblotting with an antiserum that
recognizes active Erk1 and Erk2 (Promega). Small amounts
of active Erk2 were detected in all of the nocodazole-
treated samples (z<10% of the total Erk2), and no active
Erk1 was detected (data not shown). The presence of
some active Erk2 in the nocodazole-treated cells is com-
patible with the hypothesis that XCL100’s effects on mi-
totic arrest were due to inactivation of Erk2. However,
similar amounts of active Erk2 were detected in untreated,
asynchronous cells (data not shown). In contrast, Minshull
et al. (1994) found marked differences in the activity of
Erk2 in interphase vs mitotically arrested cycling extracts.
Thus, mitotic activation of MAP kinase is either more sub-
tle or more difficult to detect in intact XTC cells than it is
in extracts.
XCL100 C260S can bind avidly to phosphorylated Erk2,
and therefore could potentially interfere with MAP kinase
function by preventing MAP kinase from interacting with
its substrates (Sun et al., 1993). However, it seems unlikely
that this type of inhibition would occur to any significant
extent at the concentration of XCL100 C260S we have
injected in our studies. Sun et al. (1993) found that expres-
sion of the C258S mutant of mouse Mkp-1 (the mouse
homolog of XCL100) in COS cells at levels substantially
greater than the levels of Erk2 resulted in the coprecipita-
tion of z30% of the cells’ Erk2 with the Mkp-1 C258S.
However, in our case, the concentration of microinjected
XCL100 C260S was z20-fold lower than the concentra-
tion of Erk2 (75 nM vs 1–2 mM). Thus, we would expect
our injected phosphatases to be able to inhibit MAP ki-
nase function only by dephosphorylation, not by seques-
tration. This is consistent with our finding here that XCL100
interfered with mitotic arrest, and XCL100 C260S did not.
Similarly, we have found that microinjection of wild-type
Table I. The Effect of Inhibiting MAP Kinase Activation
on the Spindle Assembly Checkpoint: Summary of 
Microinjection Data
Treatment
Outcome
Remained
arrested
in mitosis
through 4 h
Mitosis
completed
within 4 h
Progressed to
interphase 
within 4 h
without
completing
mitosis
Nocodazole plus buffer injection 10/10 0/10 0/10
XCL100 injection 0/20 20/20 0/20
Nocodazole plus XCL100‡ 0/15‡ 0/15‡ 15/15‡
Nocodazole plus XCL100 C260S 17/17 0/17 0/17
MKK-1* injection 0/19 19/19 0/19
Nocodazole plus XCL100 plus MKK-1* 8/8 0/8 0/8
‡The data tabulated here are taken from four independent microinjection experiments
using four separate preparations of XCL100. Three other preparations of XCL100
showed no effect (cells remained arrested in mitosis for 4 h after nocodazole treat-
ment) when microinjected into a total of about a dozen mitotic cells.The Journal of Cell Biology, Volume 137, 1997 440
XCL100 mRNA inhibits progesterone-induced oocyte mat-
uration, whereas XCL100 C260S does not (Sohaskey, M.L.,
unpublished data).
The Effect of XCL100 on Mitotic Arrest Is Due to Its 
Effects on p42 or p44 MAP Kinase
We set out to determine whether the effect of XCL100 on
mitotic arrest was due to its effect on p42/p44 MAP kinase,
p38 Hog1, or some other as yet unidentified target. Our
approach was to coinject XCL100 with a constitutively ac-
tive MAP kinase kinase (MKK-1*) (Mansour et al., 1994).
MKK-1* has no direct effect on XCL100 but exerts an ef-
fect on MAP kinase that is opposite to the effect of
XCL100: it phosphorylates the same residues that XCL100
dephosphorylates. MKK-1 is a highly specific protein ki-
Figure 5. Effects of perturbing MAP kinase function on the spindle assembly checkpoint. Mitotic cells were microinjected with the inac-
tive XCL100 C260S mutant (left), wild-type XCL100 (middle), or XCL100 plus MKK-1* (right), and then treated with nocodazole. The
morphological consequences were assessed by time-lapse video microscopy. Four images are shown from each video series. Numbers in
each panel denote the time (in h and min) after nocodazole treatment.Wang et al. MAP Kinase and the Spindle Assembly Checkpoint 441
nase. It does not phosphorylate p38 Hog1, and biochemi-
cal and genetic studies have thus far uncovered no evi-
dence for the existence of substrates of MKK-1 other than
p42 and p44 MAP kinase (Cano and Mahadevan, 1995;
Ferrell, 1996a; Lin et al., 1995; Rouse et al., 1994). Thus, if
MKK-1* were found to antagonize the effect of XCL100
on mitotic arrest, this would be strong evidence that
XCL100’s effects on mitotic arrest were due to its effect on
p42 or p44 MAP kinase.
We coinjected XCL100 (needle concentration 1.5 mM)
with MKK-1* (needle concentration 5 mM; based on in vitro
assays [Fig. 4 C], this concentration should substantially
counteract the effects of the coinjected XCL100) into XTC
cells at metaphase or prometaphase, and then immediately
treated the cells with nocodazole. We found that the in-
jected cells (8/8) did not exit mitosis; they remained blocked
at pseudo-prometaphase stage with scattered chromo-
somes for at least 4 h (Fig. 5; Table I). These findings in-
dicate that MKK-1* inhibited or overcame the effects of
XCL100 on mitotic arrest. This supports the hypothesis
that the effects of XCL100 on mitotic arrest are due to its
effects on p42 or p44 MAP kinase, rather than to some
other possible target.
Finally, we assessed whether MAP kinase activation was
sufficient to bring about metaphase arrest. We addressed
this question by injecting MKK-1* alone (needle concen-
tration 10 mM) into mitotic XTC cells. We found that mi-
croinjection of this protein did not bring about a mitotic
arrest. This finding suggests either that MAP kinase acti-
vation is not sufficient for mitotic arrest, or that we were
unable to achieve a high enough level of MAP kinase acti-
vation to bring about mitotic arrest.
Discussion
Spindle Localization of MAP Kinase Provides a Clue to 
Its Role in Mitosis
Several workers have previously examined the localization
of the Erk1 and Erk2 MAP kinases in interphase tissue-
culture cells. Erk1/Erk2 have been reported to be distrib-
uted in a diffuse (Dikic et al., 1994; Gonzalez et al., 1993;
Lenormand et al., 1993; Traverse et al., 1994) or diffusely
speckled (Chen et al., 1992) pattern in a variety of quies-
cent cells and to translocate to the nucleus when the cells
are treated with mitogens. However, recent evidence indi-
cates that, in at least some cell types, MAP kinase may con-
centrate on or around microtubules (Morishima-Kawa-
shima and Kosik, 1996; Reszka et al., 1995). Here we
found that, in interphase XTC cells, the Erk1/Erk2 distri-
bution is diffuse; we saw no examples of microtubule-like
staining in these cells.
When XTC cells entered M phase, some MAP kinase
immunofluorescence was found to concentrate in the spin-
dle. This could represent MAP kinase translocating to the
spindle or, possibly, microtubule-associated MAP kinase
undergoing some change in association that made it more
accessible to antibody staining. MAP kinase spindle stain-
ing was strongest during metaphase and decreased by
anaphase, and MAP kinase staining was absent from the
cytokinesis midbody.
In some ways, the changes in MAP kinase localization
during mitotic M phase reported here are similar to those
reported by Verlhac et al. (1993) and Choi et al. (1996) for
meiotic M phase. Verlhac et al. (1993) found MAP kinase
to concentrate at the spindle poles in mouse oocytes in
meiotic M phase and to become more diffuse in anaphase.
This is similar to our finding, except that we found MAP
kinase to be present throughout the spindle rather than
just at the spindle poles. Choi et al. (1996) found MAP ki-
nase to concentrate in the miniasters that form near the
chromosomes in mouse oocytes in early meiotic M phase,
again reminiscent of the spindle localization we found.
The presence of MAP kinase in the mitotic spindle puts
it in a position either to monitor the status of the spindle,
or to regulate spindle-associated proteins, or both. It also
places MAP kinase in the proximity of key cell cycle regu-
lators. In particular, cyclin B1/Cdc2 complexes appear to be
largely spindle associated during M phase, and a fraction
of the cyclin B2 is as well (Jackman et al., 1995; Ookata et al.,
1992, 1993, 1995; Pines and Hunter, 1991; Rattner et al.,
1990).
Microinjection of MAP Kinase Phosphatase Has No 
Apparent Effect on Mitotic Progression
Erk2 becomes activated concomitantly with Cdc2 during
oocyte maturation, and manipulations that inhibit the acti-
vation of MAP kinase (Gotoh et al., 1995; Huang and Fer-
rell, 1996a; Kosako et al., 1994b) or its upstream activators
(Freeman et al., 1990; Sagata et al., 1988) inhibit Cdc2 acti-
vation. In addition, microinjection of oocytes with consti-
tutively active MAP kinase (Haccard et al., 1995), consti-
tutively active Mek-1 (a MAP kinase kinase; Huang et al.,
1995), constitutively active Raf-1 (a MAP kinase kinase ki-
nase; Muslin et al., 1993), or Mos (a MAP kinase kinase ki-
nase; Yew et al., 1992) brings about Cdc2 activation. These
findings place Erk2 upstream of Cdc2 during meiosis and
raise the possibility that MAP kinases may be important
for Cdc2 activation at the onset of mitosis as well. It has
also been shown that purified Erk2 can cause centrosome-
nucleated microtubules to change from interphase-like sta-
bility to M-phase–like instability (Gotoh et al., 1991b). Thus,
MAP kinase could be involved in the changes in microtu-
bule dynamics that occur during both meiosis and mitosis.
However, there is conflicting evidence on whether Erk1
or Erk2 is activated during mitotic M phase (Edelmann et
al., 1996; Heider et al., 1994; Tamemoto et al., 1992), and
the question of whether Erk1 or Erk2 function is required
for entry into or progression through mitotic M phase has
not been previously addressed. In the present study we de-
tected small amounts of active Erk2 in M-phase cells but
found no indication that MAP kinase function was impor-
tant for normal mitotic progression; microinjection of the
MAP kinase phosphatase XCL100 had no obvious effect.
We cannot rule out the possibility that microinjection of a
higher concentration of XCL100, or microinjection of
XCL100 before prophase, might alter mitotic progression.
MAP Kinase Function Is Required for the Spindle 
Assembly Checkpoint
Previous work demonstrated that Xenopus egg extracts
supplemented with nuclei arrest in a mitotic state when
treated with nocodazole, and that addition of mouse MAPThe Journal of Cell Biology, Volume 137, 1997 442
kinase phosphatase (Mkp-1) to these extracts releases them
from mitotic arrest (Minshull et al., 1994). These findings
suggest a role for MAP kinase in the spindle assembly check-
point, provided the reconstituted extract system faithfully
recapitulates the checkpoint controls found in intact cells.
Here we present strong evidence that MAP kinase func-
tion is required for the spindle assembly checkpoint in in-
tact XTC cells. Microinjection of active XCL100 during
prometaphase or metaphase (but not prophase) abrogates
the normal spindle assembly checkpoint, whereas microin-
jection of saline or an engineered inactive XCL100 mutant
protein does not. Coinjection of MKK-1*, a constitutively
active MAP kinase kinase, abolishes the effect of XCL100
on the spindle assembly checkpoint. This finding argues
that the relevant target of XCL100 is p42 or p44 MAP ki-
nase, rather than p38 Hog1 or some adventitious target. It
is also possible that the relevant target is some as yet uni-
dentified protein that can be regulated by both XCL100
and MKK-1*.
Previous work has also shown that MAP kinase function
is required for the metaphase arrest that occurs naturally
during the maturation of frog oocytes (Haccard et al., 1993;
Kosako et al., 1994a; Minshull et al., 1994); i.e., MAP ki-
nase is an essential mediator of “cytostatic factor” function.
Taken together with Minshull et al.’s studies of the spindle
assembly checkpoint in extracts and the present studies of
the spindle assembly checkpoint in intact cells, it appears
that M-phase arrest in a variety of biological contexts de-
pends upon MAP kinase function. It is therefore possible
that studies of any one of these systems might yield in-
sights into all of them.
At present, the mechanism through which MAP kinase
mediates the spindle assembly checkpoint is unknown. The
possibilities can be organized into three general classes of
mechanism. (a) MAP kinase could regulate the machinery
that detects spindle misassembly or chromosome misalign-
ment. (b) MAP kinase could regulate the cyclin destruc-
tion machinery. For example, MAP kinase could regulate
whatever specific ubiquitin-conjugating enzymes are re-
sponsible for ubiquitinating cyclins B1 and B2. (c) MAP
kinase could convert cyclins B1 and B2 to phosphorylated,
nondestructible forms. This possibility is supported by the
observation that cyclin B1 is a good substrate for p42 MAP
kinase (Izumi and Maller, 1991). Cyclin B2 is not a good
substrate for Erks 1 or 2, but Minshull et al. have demon-
strated the existence of one or more cyclin B2 kinase activ-
ities that appear to be MAP kinase dependent (Minshull
et al., 1994).
Likewise, it is not understood what lies upstream of
MAP kinase in the spindle assembly checkpoint. It is un-
clear whether the checkpoint makes use of known MAP
kinase kinases (MKK-1/Mek-1, MKK-2/Mek-2) and known
MAP kinase kinase kinases (Mos, Raf-1, A-Raf, and B-Raf),
or whether there are unknown MAP kinase cascade com-
ponents used specifically for this function. Our hope is that
through a combination of in vivo analysis, like that de-
scribed here, and examination of in vitro systems, as de-
scribed previously, it may be possible to delineate the sig-
naling pathways used in the spindle assembly checkpoint
in detail.
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